Wedbush downgrades Compass Therapeutics to Neutral, sets price target to $1
Wedbush downgraded Compass Therapeutics's stock to Neutral with a price target of $1.00.The price target implies a downside of 19.4% from the Sep 22 close of $1.24.Key takeaways from the analyst noteRegulatory Challenges with Tovecimig: The FDA's indication that a new study demonstrating a survival…